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Abstract 
Schizophrenia is a chronic recurrent illness with 
positive, negative and cognitive symptoms, which 
can lead to severe impairment of psychosocial and 
occupational functioning. Antipsychotic 
medications have been available for decades in 
both oral (PO) and long-acting injectable (LAI) 
formulations, with demonstrated efficacy in 
treating positive symptoms of schizophrenia. Most 
antipsychotic medications, however, have only 
limited success in improving psychosocial and 
occupational functioning for patients. Paliperidone 
palmitate (PP) LAI has been available for the 
treatment of schizophrenia in Canada since 2010[1] 
and has shown some promising results in 
improving psychosocial and occupational 
functioning. In this article we examine the role of 
patient adherence to antipsychotic medication, the 
resulting effect on relapse, and the socioeconomic 
impact of schizophrenia. We also present 2 case 
studies where two adult female patients diagnosed 
with schizophrenia are examined in the context of 
economic, functional, cognitive and psychosocial 
outcomes, before and after treatment with PP LAI. 
Both patients and caregivers demonstrated an 
improvement in their quality of life over a 
relatively short period of time. This paper indicates 
that PP LAI has had great impact on patients’ 
quality of life and further studies should be 
conducted to verify its effectiveness. 
I. Introduction
A. Schizophrenia
Schizophrenia is a chronic disease 
characterized by positive, negative and cognitive 
symptoms.[2] These symptoms include 
delusions, hallucinations, disorganized speech 
and behaviour and/or other symptoms, which 
cause social and/or occupational dysfunction.[2] 
Approximately 1% of the world’s population and 
300,000 Canadians suffer from schizophrenia.[3] 
Every year, from a population of 100,000 people, 
20-25 people will develop this illness for the first
time.[4]
B. Psychosocial functioning of schizophrenia
Individuals with schizophrenia often 
have poor social interactions, poor work 
performance and difficulty maintaining 
meaningful relationships.[5] In one study, 72.9% 
of those with schizophrenia reported no 
employment activity.[6] Poor social functioning 
is one of the most debilitating features of 
schizophrenia, which reflects impairments in 
interpersonal relationships and 
communication.[7] Many patients with 
schizophrenia become dependent on their 
caregivers, typically family members, for 
support.[8] This results in social isolation for the 
patient aside from their caregivers.[8] Due to the 
chronic nature of the disease, caregivers become 
necessary lifetime support systems to the 
patients.[8] The caregivers are forced to change 
their life plans and they often experience 
emotional, social and financial burdens.[8,9]  
C. Cost of schizophrenia
In 2004, the total economic burden of 
this disease in Canada was $6.85 billion of 
which $4.83 billion was due to decreased 
productivity associated with morbidity and 
premature mortality due to schizophrenia.[10] 
Treatment of schizophrenia consumed 1.7% of 
the Canadian healthcare budget, making 
schizophrenia a disproportionately expensive 
disease to treat.[10] Of the health care and non-
health care related costs, 61% was due to 
hospitalization, making it the largest cost 
component of health and non-healthcare related 
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costs.[10] High relapse rates are a significant 
contributor to these high hospitalization costs. 
D. Relapses
Weiden and Olfson found in 1986 that 
the aggregate cost of readmission for 
approximately 260,000 patients with 
schizophrenia in the United States was nearly $2 
billion.[11] As well, Haya et al. found that 
patients with prior relapses incur 3 times higher 
total annual direct mental health-care costs than 
those without prior relapses over a 1-year period. 
Those with prior relapses faced higher costs of 
medication and outpatient services.[12] Many of 
those who stop treatment and then relapse are 
unable to achieve prior levels of functioning. 
This may be due to multiple relapses leading to 
continuing neurodegeneration.[13] Compared to 
patients who have relapsed, first episode patients 
have higher rates of stabilization from acute 
symptoms, lower rates of symptom exacerbation 
over a 2-year follow up, and require lower doses 
of antipsychotics for acute and maintenance 
treatment.[13] As well, first-episode patients 
experienced reduced negative symptoms and 
deficit states.[13] In first-episode patients the 
greater increase in plasma homovanillic acid 
(pHVA) after the first week of treatment is 
associated with better treatment outcome.[13] 
Antipsychotic drug response is associated with 
pHVA levels, which acts as a peripheral marker 
for dopamine activity in the brain.[14] Those 
with higher pre-treatment levels experience more 
effective therapeutic response, whereas those 
with lower levels often experience 
Parkinsonism.[15,16]  
E. Adherence
Following a psychotic episode, non-
adherence to antipsychotic (AP) medication is 
common, with non-adherence rates reaching as 
high as 50% after 1 year and 75% within 2 
years.[17] This poses a significant concern since 
adherence to antipsychotic medication appears to 
be protective against relapse. Brief periods of 
partial adherence also lead to higher relapse 
rates.[17] Patients who adhere to medication 
have a first, second and third year relapse rate of 
18%, 29% and 36% respectively.[17] 
Comparatively, patients who do not comply with 
their antipsychotic medication have first, second 
and third year relapse rates of 29%, 42% and 
57%.[17] As well, those who are non-adherent to 
medication spend an average of 38.1 days in 
hospitalization compared to those who are 
adherent who spent an average of 14.3 days.[17] 
It should be noted that small deviations in 
medication could have a significant effect on 
relapse. Missing only 25% of the medication 
dose for more than 2 weeks results in increased 
risk of relapse.[17] The average number of days 
from the beginning of non-adherence to relapse 
is 72 days.[17] Furthermore, even partial 
adherence over a short period of time can result 
in increased risk of hospitalization.[17] 
Subotnik’s group observed that patients who 
were partially adherent for less than 10 days 
results in an increased odds of hospitalization 
with an odds ratio of 1.98; for partial adherence 
for 11-30 days, the odds ratio was 2.81, and for 
over 30 days, the odds ratio was 3.96.[18] It was 
also found that partial adherence increased the 
risk of hospitalization in the long-term treatment 
of chronic schizophrenia.[17] In addition to the 
personal suffering caused by psychotic relapse, 
medication non-adherence has a tremendous 
financial cost.[17] The cost of non-adherence is 
high, with as much as 50% of the direct medical 
costs attributed to non-adherence to 
medication.[11]  
F. Long-acting injectable vs oral medication
     A systematic review done by Leucht et 
al. on antipsychotic medication identified that 
33.3% of participants on PO relapsed compared 
to 21.6% of participants on LAI.[19] As well, 
Subotnik et al. found that the 12-month relapse 
rate for participants on risperidone PO (RisO) 
was 33% compared to those on risperidone LAI 
(RLAI) of only 5%.[17] This was associated 
with a relative risk reduction for RLAI over 
RisO by 84.7%.[17] Cost calculations done by 
Koczerginski and Arshoff demonstrated that 
patients treated with RLAI in injection clinics 
saved $17,355 per patient annually in hospital 
and medication costs, when compared with PO 
medications.[20] The authors stated that this was 
due to reduced relapse rates associated LAI, 
which reduces hospital stays and emergency 
room visits through increased effectiveness of 
treatment.[20] 
When comparing long-acting injectable 
(LAI) to oral medication (PO), early episode 
patients receiving risperidone LAI have higher 
adherence and symptom control resulting in a 
non-significant increase of white matter volume 
(WMV) in the frontal lobe compared to patients 
receiving oral risperidone.[21,22] WMV increase 
is the result of increased myelination, which 
results in faster conduction in neurons.[22] 
Bartzokis et al. conducted an MRI study where 
WMV remained stable in RLAI participants but 
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decreased in RisO groups.[22] The effects of AP 
medication do not directly induce 
myelination.[22] Instead, AP medications that 
block dopamine receptors promote increased 
intracortical myelination, and in rodent models 
this exposure to AP medications promotes 
oligodendrocyte differentiation and myelin 
repair.[22] Patients on RLAI had faster reaction 
times involving frontal lobe function and had 
faster reaction time on working memory and 
mental flexibility tasks.[22] 
G. Paliperidone palmitate
  PP is an atypical long-acting injectable 
antipsychotic therapy (LAI) designed for once 
monthly intramuscular (IM) injection and is 
indicated for acute and maintenance treatment of 
adult patients with schizophrenia and 
schizoaffective disorder.[1] 
II. Case Study 1: Patient NB
The following is a case study for a 
female, aged 26, who had been diagnosed in 
2007 and 2008 with Obsessive Compulsive 
Disorder (OCD) and paranoid schizophrenia 
respectively.  Patient NB is single female with 
normal weight, unemployed, and living with her 
parents. From 2005-2006 she repeatedly dropped 
out of school and refused to leave the house. She 
was not very communicative, stopped eating for 
several weeks and lost a significant amount of 
weight. In 2007, the year NB was diagnosed with 
OCD, she started to exhibit bizarre behaviour, 
such as putting on and removing clothes, shoes, 
etc.; she would walk back and forth in a room, 
pull out tissues from tissue boxes continuously 
until the box was empty, and walk the streets to 
pick up cigarettes butts to smoke. Self- harm led 
to hospitalization: in 2008, the patient was non-
adherent to medication and attempted to commit 
suicide by jumping from the roof of her family 
home. This led to a 3-week hospital stay, during 
which time NB was diagnosed with 
schizophrenia. In 2009, she was hospitalized 
again for 3 weeks. In 2011, the patient stopped 
taking her medication and increased her 
recreational drug use. The family then took the 
patient to India to seek treatment. Upon returning 
to Canada in 2013, the patient had aggressive 
violent behaviour and used abusive language. 
She would laugh to herself and was withdrawn. 
The patient refused to sleep in her bedroom 
opting instead for the couch. She was not eating, 
would not shower for days, and maintained poor 
hygiene. She would stay up nights, just sitting on 
the couch, not doing anything. In 2014, the 
patient was admitted to the Centre for Addiction 
and Mental Health (CAMH). Her medical, 
family and social history were unremarkable. 
The patient was on sertraline HCL and 
zuclopenthixol decanoate depot. On February 
20, 2014, the medication was switched to PP 150 
mg. This dose was reduced to 100 mg but then 
was subsequently increased to 150 mg on May 
22, 2014. This change in treatment, given as 
LAI, was effective with a 100% compliance. The 
patient started to show reduction in her positive, 
negative and cognitive symptoms. NB had an 
improvement in her family interactions, started 
social activities, her speech improved 
spontaneously, her social and emotional isolation 
was reduced and she became less suspicious. 
After the switch to PP, the patient was able to 
maintain good eye contact and her personal 
hygiene improved, even going as far as the 
application of makeup. Furthermore, she was 
able to watch television with her parents, ask her 
parents questions, talk to her grandparents in 
India, clean her room, talk to people if they 
initiated the conversation and eat regular meals. 
NB now wants to volunteer and take a 
reintegration course at George Brown College. In 
the future she wishes to attend university and get 
a job in management. Prior to PP treatment, the 
patient had three hospitalizations, cumulating in 
a 59-day length of stay. She also had 3 ER visits. 
After switching, the patient had no 
hospitalizations and no ER visits. NB’s caregiver 
was interviewed and a Zarit Burden Caregiver 
score was determined. Prior to treatment, the 
caregiver’s interview was ranked at a score of 
88, the highest possible score and considered a 
severe burden (61-88).[23] However, after one 
year of treatment the family reported an 
improvement in her psychosocial function and 
after 2 years of treatment the total score was 
reduced to 36, which is considered a mild to 
moderate burden (21-40).[23] The patient was 
ranked on a Personal and Social Performance 
scale (PSP), which is considered to be one of the 
most effective scales for assessing changes in 
functionality in a clinical setting due to its 
sensitivity to change and brevity.[24] Before 
starting treatment with PP, NB was ranked at 20 
out of 100: she had very severe difficulties in 
aggressive behaviour and severe impairment of 
personal and social functioning. After taking PP, 
her score increased to 70, which indicates 
manifest but not marked difficulties. She also 
took a Medication Satisfaction Questionnaire, 
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where the patient identified that she was very 
satisfied with the medication with a score of 6 
out of 7. The patient stated that she is now “more 
happy”. To measure the quality of life, patient 
NB took the S-QoL questionnaire. The S-QoL is 
a self-administrated questionnaire used to 
measure the quality of life of those suffering 
from schizophrenia.[25,26] This 
multidimensional instrument has been 
demonstrated by Auquier et al. to be effective in 
measuring a patients perspective of their 
psychological well-being, self-esteem, family 
relationships, relationships with friends, 
resilience, physical well-being, autonomy and 
sentimental life.[26] This scale has been shown 
to be sensitive to change, reproducible, 
responsive and has high construct validity and 
internal consistency reliability.[26] Prior to LAI 
treatment, NB marked 95% of the 41 items as 
“much less” to “less” than she preferred. After 
the treatment with LAI, she marked only 15% of 
the items, as “much less” to “less” than she 
preferred. 
III. Case study 2: Patient XD
The following is a case study for a 30-
year-old female (XD). In Grade 4 she was 
considered a gifted student. In 1998 she was 
diagnosed with a brain tumour. In the year 2000, 
the tumour was surgically removed. In 2002, XD 
attended the University of Toronto for 
English/Psychology. Two years later, she was 
hospitalized at Credit Valley Hospital (CVH) for 
2 weeks, as a result of anxiety. XD’s symptoms 
included paranoid ideation, losing concentration, 
an inability to complete assignments and she 
failed courses. In 2010, she was put on probation 
and later she was suspended from the University 
due to failing grades. In 2013, with worsening 
symptoms, the patient was found wandering the 
streets by police. She was subsequently admitted 
to CVH for 55 days with the diagnosis of 
schizophrenia. In July of that year, she was 
discharged with a prescription for RisO 2 mg per 
day. Due to lack of efficacy, in August 2013 she 
was started on PP 100 mg IM. In September of 
that year, she returned to school, gradually 
increasing the number of courses she was taking. 
In 2016, she successfully completed 4 courses 
with grades in the 80s, which, according to the 
University of Toronto, is considered to be an 
excellent academic standing.[27] Now she plans 
to pursue a master’s degree. XD currently 
attends church and volunteers at the Acquired 
Brain Injury Association. She reports a “good 
relationship with people and classmates”. Her 
family life has also “improved tremendously” 
and she is able to take her parents out. She 
started to trust her parents and is no longer 
fighting with them. They have stated that things 
are “very peaceful”, that XD “involves in 
conversation” and that they have a “very good 
relationship”. The family has even gone as far as 
to say, “With medication our daughter has no 
mental illness.” These improvements were 
noticed within a year. This change was further 
exemplified by the change in her caregivers’ 
Zarit Burden Caregiver score. Prior to treatment, 
her caregivers had a score of 73, which is 
classified as a severe burden (61-88). After two 
years of treatment her caregivers had a score of 
24, which is classified as a mild to moderate 
burden (21-40).[23] As well, on the PSP, the 
patient showed major improvements. Prior to 
switching to PP 100 mg IM, XD scored only 15, 
due to very severe impairment in personal and 
social functioning; but after 2 years of treatment, 
this score rose to 90, which indicates almost no 
impairment. As well, based on the Medication 
Satisfaction Questionnaire, XD’s caregivers 
reported a score of 6 indicating that they were 
very satisfied. Prior to treatment with LAI, out of 
the maximum 41 items of the S-QoL 
questionnaire, patient XD marked 100% as 
“much less” to “less” than she preferred. After 
the treatment with LAI, she marked only 2.5% as 
“much less” to “less” than she preferred. 
IV. Discussion
Non-adherence limits the efficacy of 
pharmacotherapy resulting in recurrence of 
episodes of schizophrenia symptoms. These 
repeated episodes result in increased 
hospitalization, decreased effectiveness of 
treatment outcomes, worsening psychosocial 
functioning, and a lower quality of life. As a 
result, relapse prevention is critical. LAIs have 
been shown to be more cost-effective than other 
PO treatments. LAIs also improve clinical 
outcomes, decrease hospitalizations and maintain 
frontal lobe myelination. LAIs are associated 
with increased adherence, leading to greater 
relapse prevention, better psychotic symptom 
control and improved cognitive functioning. The 
cases presented here further demonstrate that the 
LAI PP significantly improved adherence, 
symptoms, and particularly improved 
psychosocial occupational functioning in the two 
adult patients described. Both patients and their 
families reported clinically significant 
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improvements as a result of the medication. 
Simultaneously, both patients had a 100% 
adherence rate and neither experienced a relapse. 
The cases presented indicate promising results in 
improving psychosocial and occupational 
functioning associated with PP, however, further 
studies with larger sample sizes and robust 
methodologies are required. 
V. Acknowledgment
The authors would like to express their thanks to 
Sarah Harrison of Janssen Pharmaceutical for her 
scientific support in the preparation of this 
article.  
VI. References
[1] Saklad S. Formulary Monograph Paliperidone Palmitate 
Extended-Release Injectable Suspension (Invega ®
Sustenna™). 1st ed. San Antonio: University of Texas Health
Science Center; 2010. 
[2] Schizophrenia [Internet]. 1st ed. American Psychiatric 
Publishing; 2015 [cited 14 July 2016]. 
[3] Schizophrenia Society of Ontario - About Schizophrenia 
[Internet]. Schizophrenia.on.ca. 2016 [cited 14 July 2016]. 
[4] Lieberman J, Perkins D, Belger A, Chakos M, Jarskog F,
Boteva K et al. The early stages of schizophrenia: 
speculations on pathogenesis, pathophysiology, and 
therapeutic approaches. Biological Psychiatry.
2001;50(11):884-897. 
[5] Green M, Kern R, Braff D, Mintz J. Neurocognitive 
Deficits and Functional Outcome in Schizophrenia: Are We
Measuring the "Right Stuff"?. Schizophrenia Bulletin. 
2000;26(1):119-136. 
[6] Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, 
Perkins D et al. Barriers to Employment for People With 
Schizophrenia. American Journal of Psychiatry.
2006;163(3):411-417. 
[7] Chambon V, Pacherie E, Barbalat G, Jacquet P, Franck N, 
Farrer C. Mentalizing under influence: abnormal dependence 
on prior expectations in patients with schizophrenia. Brain. 
2011;134(12):3728-3741. 
[8] Jungbauer J, Stelling K, Dietrich S, Angermeyer M.
Schizophrenia: problems of separation in families. J Adv 
Nurs. 2004;47(6):605-613. 
[9] Milliken Rodney P. Parents as Caregivers for Children 
with Schizophrenia: Moral Dilemmas and Moral Agency.
Issues in Mental Hlth Nursing. 2003;24(8):757-773. 
[10] Goeree, R. et al. The Economic Burden Of 
Schizophrenia In Canada In 2004. Current Medical Research 
and Opinion 2005;21.12: 2017-2028. Web.
[11] Weiden, P. J. and M. Olfson. Cost of relapse in 
Schizophrenia. Schizophrenia Bulletin. 1995;21.3:419-429. 
Web.
[12] Ascher-Svanum, Haya et al. The Cost of Relapse and the 
Predictors of Relapse in the Treatment of Schizophrenia. 
BMC Psychiatry 2010;10.1: 2. Web.
[13] Leiberman, JA. Factors Influencing Treatment Response 
and Outcome of First-Episode Schizophrenia: Implications 
for Understanding the Pathophysiology of Schizophrenia. J 
Clin Psychiatry. 1996;57.9:5-9. Print. 
[14] Amin F, Davidson M, Davis K. Homovanillic Acid 
Measurement in Clinical Research: A Review of
Methodology. Schizophrenia Bulletin. 1992;18(1):123-148. 
[15] Koreen A, Lieberman J, Alvir J, Mayerhoff D, Loebel
A, Chakos M et al. Plasma homovanillic acid in first-episode 
schizophrenia: Psychopathology and treatment response. 
Schizophrenia Research. 1993;9(2-3):240. 
[16] Chakos M, Alvir J, Koreen A, Sheitman B, Geisler S,
Lieberman J. Incidence and correlates of acute 
extrapyramidal symptoms in first episode schizophrenia. 
Schizophrenia Research. 1995;15(1-2):205. 
[17] Subotnik K, Nuechterlein K, Ventura J, Gitlin M, 
Marder S, Mintz J et al. Risperidone Nonadherence and 
Return of Positive Symptoms in the Early Course of
Schizophrenia. American Journal of Psychiatry.
2011;168(3):286-292. 
[18] Weiden P, Kozma C, Grogg A, Locklear J. Partial 
Compliance and Risk of Rehospitalization Among California 
Medicaid Patients With Schizophrenia. PS. 2004;55(8):886-
891. 
[19] Leucht C et al. Oral Versus Depot Antipsychotic Drugs
for Schizophrenia—A Critical Systematic Review and Meta-
Analysis of Randomised Long-Term Trials. Schizophrenia 
Research. 2011;127.1-3:83-92. Web.
[20] Koczerginski D and Arshoff L. Hospital Resource Use 
by Patients with Schizophrenia: Reduction after Conversion 
from Oral Treatment to Risperidone Long-Acting Injection. 
Healthc Q 2011;14.1: 82-87. Web.
[21] Keith, Samuel. Use of Long-Acting Risperidone in 
Psychiatric Disorders: Focus On Efficacy, Safety and Cost–
Effectiveness. Expert Review of Neurotherapeutics. 2009;
9.1: 9-31. Web.
[22] Bartzokis G et al. Long Acting Injection Versus Oral 
Risperidone in First-Episode Schizophrenia: Differential 
Impact On White Matter Myelination Trajectory.
Schizophrenia Research. 2011;132.1:35-41. Web. 
[23] Rankin E. D. et al. The Establishment of Clinical 
Cutoffs in Measuring Caregiver Burden in Dementia. The 
Gerontologist. 1994;34.6:828-832. Web.
[24] Brissos S, Molodynski A, Dias V, Figueira M. The 
importance of measuring psychosocial functioning in 
schizophrenia. Ann Gen Psychiatry. 2011;10(1):18.
[25] Lancon C, Reine G, Simeoni M, Aghababian V, Auquier 
P. Development and validation of a self rating quality of life 
scale: the S-QoL. L'Encéphale. 2016;33(3):277-84. 
[26] Auquier P, Simeoni M, Sapin C, Reine G, Aghababian 
V, Cramer J et al. Development and validation of a patient-
based health-related quality of life questionnaire in 
schizophrenia: the S-QoL. Schizophrenia Research. 
2003;63(1-2):137-149. 
[27] Grading Policies — Newly Admitted Students 
[Internet]. Artsci.utoronto.ca. 2016 [cited 10 July 2016].
GSTF Journal of Advances in Medical Research (JAMR) Vol.1 No.4, 2016
©The Author(s) 2016. This article is published with open access by the GSTF
Authors’ Profiles 
Dr. Sunny Johnson1, BSc., MD, FRCPC 
Dr. Sunny Johnson is a Consultant Psychiatrist at 
Credit Valley Hospital, Ontario, Canada. He is 
also the Director of Medical Research 
Associates. He graduated from University of 
Padova (MD) and did his residency in psychiatry 
(FRCP) at Memorial University, Newfoundland, 
Canada. He is a lecturer at the University of 
Toronto and was a Clinical Assistant Professor 
for Faculty of Medicine, Memorial University. 
His clinical interest center on schizophrenia and 
mood disorders. He has participated in more than 
70 clinical trials and co-authored many articles. 
He is also involved in teaching medical students 
from All Saints University and Texila American 
University. Email: medresearch@rogers.com 
Raheem Remtulla2 
Raheem Remtulla is a Bachelor of Health 
Sciences candidate at McMaster University. He 
is a Co-President of the Student International 
Health Initiative at McMaster University and the 
McMaster Hearing Society and is a Standardized 
Patient for the University of Toronto, Faculty of 
Medicine. He has been a research assistant for 
four years at Medical Research Associates and is 
a Senate Scholar. Raheem is also on the board of 
the SMSA Scholarship. Email : 
remtulr@mcmaster.ca 
Ryan C Poolay3 
Ryan C Poolay is a 4th year medical student at 
All Saints University. He worked as a research 
assistant at Medical Research Associates. He has 
a diploma in Recreation from Seneca College, 
Toronto, Canada.  
Email: ryan.poolay@hotmail.com 
Sahar Arshed4, MD 
Sahar Arshed is an international medical 
graduate from Texila American University, 
Sparendaam, Guyana. 
Email: sahar.arshed@live.ca 
GSTF Journal of Advances in Medical Research (JAMR) Vol.1 No.4, 2016
©The Author(s) 2016. This article is published with open access by the GSTF
